DGAP-Adhoc: Carl Zeiss Meditec AG expects revenue for fiscal year 2019/20 of approx. EUR 1.3 billion
|
DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): 9 Month figures/Forecast
Carl Zeiss Meditec AG expects revenue for fiscal year 2019/20 of approx. EUR 1.3 billion
15-Jul-2020 / 09:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
| Carl Zeiss Meditec AG expects revenue for fiscal year 2019/20 of approx. EUR 1.3 billion |
Jena, July 15, 2020
In view of the continuing Covid-19 pandemic and its impact on relevant markets, Carl Zeiss Meditec AG (ISIN: DE0005313704) expects to see a further impact on business development in the remainder of fiscal year 2019/20 compared to previous year.
Assuming a recovery in markets and, in particular, that no significant additional measures to contain the Covid-19 pandemic will impact development, management anticipates revenue of around EUR 1.3 billion for fiscal year 2019/20 (previous year EUR 1.459 billion).
In the first nine months of fiscal year 2019/20, Carl Zeiss Meditec has achieved revenue of EUR 967.9 million (previous year EUR 1,027.6 million). This corresponds to a decline of 5.8% vs. the previous year. After adjustment for currency effects[1], the decline amounted to 6.9%.
Earnings before interest and taxes (EBIT) amounted to EUR 111.9 million after the first nine months of 2019/20 (previous year: EUR 184.2 million). Earnings per share (EPS) were EUR 0.77 (previous year: EUR 1.22).
The quarterly statement of the first nine months of fiscal year 2019/20 will be published on August 5, 2020. |
| |
Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: [email protected]
[1] Currency-adjusted revenue growth is calculated by converting current period revenue with the exchange rates of the previous year's period.
15-Jul-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
| Language: |
English |
| Company: |
Carl Zeiss Meditec AG |
|
Göschwitzer Str. 51-52 |
|
07745 Jena, Germany |
|
Germany |
| Phone: |
+49 (0)3641 220-0 |
| Fax: |
+49 (0)3641 220-112 |
| E-mail: |
[email protected] |
| Internet: |
www.zeiss.de/meditec-ag/ir |
| ISIN: |
DE0005313704 |
| WKN: |
531370 |
| Indices: |
MDAX, TecDAX |
| Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1093951 |
| |
| End of Announcement |
DGAP News Service |
1093951 15-Jul-2020 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
1.189,90 |
1.280,86 |
1.459,32 |
1.335,45 |
1.646,79 |
1.902,84 |
2.089,30 |
| EBITDA1,2 |
205,07 |
228,41 |
313,03 |
237,98 |
435,20 |
466,65 |
422,19 |
| EBITDA-Marge3 |
17,23 |
17,83 |
21,45 |
17,82 |
26,43 |
24,52 |
|
| EBIT1,4 |
180,83 |
197,13 |
264,66 |
177,55 |
373,61 |
396,88 |
348,12 |
| EBIT-Marge5 |
15,20 |
15,39 |
18,14 |
13,30 |
22,69 |
20,86 |
16,66 |
| Jahresüberschuss1 |
135,78 |
126,23 |
160,58 |
123,42 |
237,52 |
295,91 |
292,01 |
| Netto-Marge6 |
11,41 |
9,86 |
11,00 |
9,24 |
14,42 |
15,55 |
13,98 |
| Cashflow1,7 |
37,73 |
187,21 |
219,63 |
178,53 |
362,66 |
188,20 |
250,86 |
| Ergebnis je Aktie8 |
1,57 |
1,41 |
1,79 |
1,37 |
2,64 |
3,29 |
3,25 |
| Dividende8 |
0,55 |
0,55 |
0,65 |
0,50 |
0,90 |
1,10 |
0,42 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Carl Zeiss Meditec |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 531370 |
98,600 |
Halten |
8.818,84 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 27,77 |
35,07 |
0,79 |
48,33 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 4,28 |
35,15 |
4,22 |
18,82 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 1,10 |
1,10 |
1,12 |
21.03.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 09.02.2024 |
08.05.2024 |
06.08.2024 |
12.12.2023 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -10,66% |
2,57% |
-0,24% |
-20,10% |
|
|
Carl Zeiss Meditec AG DE0005313704